Physician profile
Bruce Akuna
NPI 1326099516
$5,314.76
in general payments reported to CMS, 2019-2025
32 companies · $1,852 in 2025
The $1,852 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,738 · 2024: $1,725 · 2025: $1,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,314.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,076.44 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $725.62 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $491.38 | 2023-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $461.85 | 2023-2025 | Qulipta, Ubrelvy, Vraylar |
| Otsuka America Pharmaceutical, INC. | $445.12 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Dexcom, INC. | $310.09 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Lilly USA, LLC | $213.27 | 2023-2025 | Mounjaro, Jardiance, Kisunla |
| Exact Sciences Corporation | $207.94 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $205.22 | 2023-2025 | Auvelity, Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.15 | 2023-2025 | Xifaxan |
| Abbott Laboratories | $137.40 | 2023-2025 | Freestyle Libre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.82 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.01 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $92.21 | 2023-2025 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $89.25 | 2024-2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $64.58 | 2024 | |
| Globus Medical, INC. | $56.99 | 2025 | Senza |
| Xeris Pharmaceuticals, INC. | $55.96 | 2023-2024 | Keveyis |
| Novartis Pharmaceuticals Corporation | $40.34 | 2023-2024 | |
| Insulet Corporation | $36.20 | 2023 | Omnipod |
| Pfizer INC. | $34.52 | 2025 | |
| Sumitomo Pharma America, INC. | $31.12 | 2025 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $28.91 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $27.83 | 2023 | Livalo, Seglentis |
| Astellas Pharma US INC | $25.48 | 2025 | Veozah |
| Amneal Pharmaceuticals LLC | $19.48 | 2025 | Crexont |
| Shield Therapeutics INC | $16.56 | 2023 | Accrufer |
| Janssen Pharmaceuticals, INC | $15.09 | 2023 | Spravato |
| Electromed, INC. | $14.43 | 2025 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $14.02 | 2023 | |
| Endogastric Solutions, INC | $7.81 | 2023 | Esophyx |
| Corium, LLC | $6.67 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Akuna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.